Palatin Technologies’ Vyleesi (bremelanotide injection) Receives FDA’s Approval for Premenopausal Women with Acquired, Generalized Hypoactive Sexual Desire Disorder

Palatin Technologies’ Vyleesi (bremelanotide injection) Receives FDA’s Approval for Premenopausal Women with Acquired, Generalized Hypoactive Sexual Desire Disorder

Shots:

  • Vyleesi (SC) is a pre-filled autoinjector pen used in anticipation of a sexual encounter melanocortin receptor agonist, approved for premenopausal women experiencing distress or interpersonal difficulty due to low sexual desire
  • In 2017, Palatin signed an agreement with AMAG pharmaceuticals for commercialization of Vyleesi. Palatin to receive $60M on FDA’s approval with milestones based on annual net sales thresholds, from $25M to evaluating $250M
  • Vyleesi can be auto injected woman’s abdomen or thigh at least 45mins before anticipated sexual activity and can be taken at any time of day and the company also plans for its availability in n Sept,2019 through select specialty pharmacies

Click here to read full press release/ article | Ref: Globe News wire | Image: Signbox